FILE:MYL/MYL-8K-20050719131543.txt.gz
EVENTS:	Other Events
TEXT:
ITEM: Other Events
 
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Item 8.01. Other Events.
     On July 15, 2005, the U.S. Food and Drug Administration (the "FDA") issued a Public Health Advisory regarding the safe use of transdermal fentanyl patches and its investigation regarding these patches. During a conference call held July 19, 2005, Mylan Laboratories Inc., a Pennsylvania corporation ("Mylan" or the "Company"), provided the information below regarding its fentanyl product.
In addition, during the conference call on July 19, 2005, Robert J. Coury, Vice Chairman and Chief Executive Officer of Mylan, said:
In emphasizing that there have been no new developments brought to the Company's attention as to the safety of these products, Mr. Coury continued:
      The FDA's investigation regarding the safe use of transdermal fentanyl patches is continuing and has not been completed. See "Risk Factors" in the Company's Form 10-K for the fiscal year ended March 31, 2005 for a discussion of the risks and uncertainties regarding the Company's business, including the potential risks inherent in any regulatory investigation such as the FDA investigation referred to above.
 
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


